Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Tobacco users with HPV-positive head and neck cancers at increased risk of recurrence

Patients with head and neck cancer linked to high risk human papillomavirus, or HPV, have worse outcomes if they are current or former tobacco users, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

15 Feb 2010

CROF, sanofi-aventis announce the creation of CASARIA for cancer research

The Canadian Radiation Oncology Foundation and sanofi-aventis are pleased to announce the creation of the Canadian Radiation Oncology Foundation/Sanofi-Aventis Research Innovation Award (CASARIA).

15 Feb 2010

Free educational webinar: Important aspects to be aware of when selecting EHR system

Community oncologists, practice administrators (PAs), executive directors (EDs), and clinical staff interested in learning the most important aspects to be aware of when selecting the Electronic Health Record (EHR) system most appropriate for your particular practice are invited to attend a free webinar at 2 p.m. EST (11 a.m. PST) on Thursday, Feb. 18, 2010.

15 Feb 2010

Symposium exploring future of cancer research to be hosted at GUMC

The Georgetown Lombardi Comprehensive Cancer Center hosts a symposium exploring the future of cancer research on Feb. 17th at Georgetown University Medical Center. Sponsored by the Ruesch Center for the Cure of Gastrointestinal Cancers, the two-part symposium, "Fighting a Smarter War Against Cancer: Personalized Medicine & the Cure for Cancer," will offer a focus on personalized medicine by bringing together experts in academia, industry and advocacy.

15 Feb 2010

Histone modifications associated with pancreatic cancer development and progression

Specific chemical modifications to proteins called histones, which are found in the nucleus of cells and act as spools around which DNA is wound, can be used to predict prognosis and response to treatment in subsets patients with pancreatic cancer, a study by researchers at UCLA's Jonsson Comprehensive Cancer Center has found.

12 Feb 2010

Study shows benefits of stent grafts over balloon angioplasty for patients who undergo dialysis

A randomized multicenter study of 190 patients at 13 medical centers shows-- for the first time-- the "superior" benefit of stent grafts over balloon angioplasty for maintaining function of dialysis access grafts in kidney failure patients who undergo dialysis. Until now, no other therapy has proven more effective than angioplasty.

12 Feb 2010

Third party reexamination of Phase III study of Ereska meets primary endpoint

Javelin Pharmaceuticals, Inc. today announced that a reexamination conducted by a third party of pain score measurements from its Phase III study of Ereska™ (intranasal ketamine) showed that top line results for its primary endpoint were statistically significant. Previously, Javelin had reported that the top line results for its primary endpoint were not statistically significant.

12 Feb 2010

CapitalBio officially joins Roche NimbleGen CSP Program

Roche NimbleGen announced today that Beijing-based genomic services provider CapitalBio has officially joined the Roche NimbleGen Certified Service Provider (CSP) Program.

12 Feb 2010

NMDP Phase III filgrastim trial: Biologics to provide pharmacy management services

Biologics, Inc., the leading cancer management company in the United States, announces that its Oncology Clinical Trial Services division has been selected by the National Marrow Donor Program® (NMDP), a nonprofit organization that facilitates unrelated hematopoietic cell transplants.

12 Feb 2010

Second-quarter fiscal 2010 results announced by Pharmacyclics

Pharmacyclics, Inc. today reported financial results for its second fiscal quarter ended December 31, 2009.

12 Feb 2010

3SBio, Ascentage Pharma announce cancer therapeutics collaboration

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd. ("Ascentage Pharma") announced today that they have formed a strategic alliance to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis. The alliance will leverage Ascentage Pharma's expertise in structure-based small molecule design, lead optimization and preclinical development with 3SBio's proven drug development and commercialization capabilities in China.

12 Feb 2010

MacSpeech Scribe Medical add-on component released

MacSpeech, Inc. today announced MacSpeech Scribe Medical, an add-on component that incorporates the world's most advanced personal transcription for the Macintosh with MacSpeech Dictate Medical, the medical professional's speech recognition solution for the Macintosh.

12 Feb 2010

Fourth-quarter and full-year 2009 results announced by Quidel

Quidel Corporation, a leading provider of rapid point-of-care diagnostic tests, announced today financial results for the fourth quarter and full year ended December 31, 2009.

12 Feb 2010

RadPharm and Medifacts International announce merger

RadPharm Inc., a leading Imaging Core Laboratory, and Medifacts International, Inc., a leading Cardiovascular Core Laboratory, today announced the merger of their business operations. The combined company will be named CoreLab Partners ("CoreLabs") and will have its corporate headquarters in Princeton, New Jersey.

11 Feb 2010

Theragenics announces record $18.7M consolidated revenue for fourth-quarter 2009

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the fourth quarter and year ended December 31, 2009. Consolidated results include the results of NeedleTech Products, Inc. (“NeedleTech”) subsequent to its acquisition by Theragenics on July 28, 2008.

11 Feb 2010

Lack of provider status denies radiation oncologists authority to make decisions based on patient safety and treatment accuracy

Our members deeply regret the needless tragedies outlined in the Times articles and express our sympathy to the families who have lost loved ones and witnessed their suffering. Our hearts also go out to all others whose lives have been impacted by these tragedies including therapists, physicians and physicists. We feel that, as radiation oncology professionals, we are all, directly or indirectly, responsible for these disastrous treatment errors and we therefore must, in future, take a more active role to assure episodes like these are never repeated.

11 Feb 2010

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2009. For the three months ended December 31, 2009, Alexion Pharmaceuticals, Inc. ("Alexion" or, the "Company") reported net product sales of Soliris® (eculizumab) of $110.6 million, reflecting strong additions of new patients, compared to $77.4 million for the same period in 2008.

11 Feb 2010

PAREXEL International, Proteome Sciences form biomarker alliance

PAREXEL International Corporation, a leading global biopharmaceutical services provider, and Proteome Sciences plc, a leading provider of protein biomarker discovery, validation, and assay development services, today announced the formation of an alliance focused on enhancing PAREXEL's biomarker capabilities for early phase clinical development. PAREXEL is using Proteome Sciences' PS Biomarker Services™ protein and peptide biomarker capabilities to support biopharmaceutical companies in making earlier assessments of new compounds in development.

From Parexel 11 Feb 2010

4SC AG announces the first treatment in Phase I clinical study of 4SC-205

4SC AG a drug discovery and development company focused on autoimmune and cancer indications, today announced the first treatment in a Phase I study evaluating 4SC-205, an oral Eg5 kinesin spindle protein inhibitor, in patients with solid tumours or malignant lymphomas.

11 Feb 2010

Bard FLAIR Endovascular Stent Graft more effective than balloon angioplasty for failing dialysis grafts

C. R. Bard, Inc. today announced the publication of trial results by The New England Journal of Medicine (NEJM) showing the Bard FLAIR® Endovascular Stent Graft maintains the patency of dialysis access grafts more effectively than balloon angioplasty alone. The FLAIR® Endovascular Stent Graft is the only implant approved by the U.S. Food and Drug Administration for use in the treatment of stenoses at the venous anastomosis of ePTFE or other synthetic arteriovenous access grafts.

11 Feb 2010

Oncology News and Research

Further Reading

Tobacco users with HPV-positive head and neck cancers at increased risk of recurrence

CROF, sanofi-aventis announce the creation of CASARIA for cancer research

Free educational webinar: Important aspects to be aware of when selecting EHR system

Symposium exploring future of cancer research to be hosted at GUMC

Histone modifications associated with pancreatic cancer development and progression

Study shows benefits of stent grafts over balloon angioplasty for patients who undergo dialysis

Third party reexamination of Phase III study of Ereska meets primary endpoint

CapitalBio officially joins Roche NimbleGen CSP Program

NMDP Phase III filgrastim trial: Biologics to provide pharmacy management services

Second-quarter fiscal 2010 results announced by Pharmacyclics

3SBio, Ascentage Pharma announce cancer therapeutics collaboration

MacSpeech Scribe Medical add-on component released

Fourth-quarter and full-year 2009 results announced by Quidel

RadPharm and Medifacts International announce merger

Theragenics announces record $18.7M consolidated revenue for fourth-quarter 2009

Lack of provider status denies radiation oncologists authority to make decisions based on patient safety and treatment accuracy

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

PAREXEL International, Proteome Sciences form biomarker alliance

4SC AG announces the first treatment in Phase I clinical study of 4SC-205

Bard FLAIR Endovascular Stent Graft more effective than balloon angioplasty for failing dialysis grafts

Cancer Research eBook

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News